Data science is shaping our discovery and development efforts
We are using advanced data science and neuroinformatics to map drug targets to specific brain circuitry and corresponding behaviors.
Stay informed about our latest developments
- January 23, 2020 BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders
- December 11, 2019 BlackThorn Therapeutics Reports Data Supporting Phase 2 Development of KOR Antagonist, BTRX-335140, in Depression and Other CNS Disorders
- October 23, 2019 BlackThorn Therapeutics Reports New Insights into Neurobehavioral Disorders at the 49th Annual Meeting of the Society for Neuroscience